CC-122

DRUG14 trials

Sponsors

Celgene, H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb

Conditions

Carcinoma, HepatocellularClinical Pharmacology, Healthy Male Volunteer StudyGlioblastomaHealthy VolunteerHealthy VolunteersLeukemia, Lymphocytic, Chronic, B-CellLymphomaLymphoma, Follicular

Phase 1

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

CompletedNCT01421524

CelgeneGlioblastoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse +3

Start: 2011-09-12End: 2023-11-21Updated: 2023-12-12

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

TerminatedNCT02031419

CelgeneLymphoma, Large B-Cell, Diffuse

Start: 2013-12-18End: 2023-12-12Updated: 2024-01-18

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

CompletedNCT02049528

CelgeneClinical Pharmacology, Healthy Male Volunteer Study

Start: 2014-01-16End: 2014-02-08Updated: 2019-11-12

Radiolabeled Study of CC-122 in Healthy Subjects

CompletedNCT02234999

CelgeneHealthy Volunteers

Start: 2014-09-23End: 2014-10-08Updated: 2019-11-12

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

TerminatedNCT02323906

CelgeneCarcinoma, Hepatocellular

Start: 2015-01-16End: 2016-12-21Updated: 2017-03-20

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CompletedNCT02406742

CelgeneLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2015-07-27End: 2020-07-07Updated: 2021-09-20

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

CompletedNCT02417285

CelgeneLymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2015-05-22End: 2023-09-28Updated: 2023-10-23

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

TerminatedNCT02509039

CelgeneLymphoma, Non-Hodgkin

Start: 2015-09-02End: 2023-05-09Updated: 2024-09-23

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

CompletedNCT02859324

CelgeneCarcinoma, Hepatocellular

Start: 2016-09-20End: 2020-03-27Updated: 2021-05-11

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

CompletedNCT03097016

CelgeneRenal Insufficiency

Start: 2017-03-30End: 2017-12-23Target: 48Updated: 2018-04-26

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

CompletedNCT03310619

CelgeneLymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2017-12-20End: 2023-02-15Updated: 2024-04-04

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

CompletedNCT03340662

CelgeneHealthy Volunteer

Start: 2017-11-09End: 2018-01-27Updated: 2019-01-16

A Rollover Study of CC-122

Active, not recruitingNCT05688475

Bristol-Myers SquibbNon-Hodgkin Lymphoma

Start: 2023-04-11End: 2026-10-31Target: 12Updated: 2026-05-11

Phase 2

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

CompletedNCT03834623

H. Lee Moffitt Cancer Center and Research InstituteMelanoma

Start: 2019-05-14End: 2021-08-04Updated: 2022-10-05

Related Papers

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Blood2023-11-02

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

eJHaem2022-02-1415 citations

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

eJHaem2022-01-146 citations

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Blood2021-11-051 citations

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

UNC Libraries2021-03-2711 citations

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Blood2020-11-053 citations

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Blood2020-11-04

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.

2020-08-0320 citations

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood2020-01-2469 citations

Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent

Blood2020-01-2317 citations

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood2019-11-13

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Blood2019-11-13

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Blood2019-11-13

Abstract 2320: Avadomide (CC-122) increases effector function and reverses exhaustion in chronically stimulated lisocabtagene maraleucel anti-CD19 CAR T drug product

Cancer Research2019-07-012 citations

Abstract 2320: Avadomide (CC-122) increases effector function and reverses exhaustion in chronically stimulated lisocabtagene maraleucel anti-CD19 CAR T drug product

Immunology2019-07-01

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Blood2018-11-297 citations

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood2018-11-294 citations

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Blood2018-11-292 citations

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Blood2018-11-29

10 more papers not shown